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Abstract
Background: Considerable public health efforts are ongoing Canada-wide to reduce the prevalence of smoking in the
general population. From 1985 to 2005, smoking rates among adults decreased from 35% to 19%, however, since that
time, the prevalence has plateaued at around 18-19%. To continue to reduce the number of smokers at the population
level, one option has been to translate interventions that have demonstrated clinical efficacy into population level
initiatives. Nicotine Replacement Therapy (NRT) has a considerable clinical research base demonstrating its efficacy and
safety and thus public health initiatives in Canada and other countries are distributing NRT widely through the mail.
However, one important question remains unanswered - do smoking cessation programs that involve mailed
distribution of free NRT work? To answer this question, a randomized controlled trial is required.
Methods/Design: A single blinded, panel survey design with random assignment to an experimental and a
control condition will be used in this study. A two-stage recruitment process will be employed, in the context of a
general population survey with two follow-ups (8 weeks and 6 months). Random digit dialing of Canadian home
telephone numbers will identify households with adult smokers (aged 18+ years) who are willing to take part in a
smoking study that involves three interviews, with saliva collection for 3-HC/cotinine ratio measurement at baseline
and saliva cotinine verification at 8-week and 6-month follow-ups (N = 3,000). Eligible subjects interested in free
NRT will be determined at baseline (N = 1,000) and subsequently randomized into experimental and control
conditions to receive versus not receive nicotine patches. The primary hypothesis is that subjects who receive
nicotine patches will display significantly higher quit rates (as assessed by 30 day point prevalence of abstinence
from tobacco) at 6-month follow-up as compared to subjects who do not receive nicotine patches at baseline.
Discussion: The findings from the proposed trial are timely and highly relevant as mailed distribution of NRT
require considerable resources and there are limited public health dollars available to combat this substantial
health concern. In addition, findings from this randomized controlled trial will inform the development of models
to engage smokers to quit, incorporating proactive recruitment and the offer of evidence based treatment.
Trial Registration: ClinicalTrials.gov: NCT01429129
Background
Smoking is a leading cause of preventable death world-
wide and the leading cause of preventable cancer death.
Tobacco use is responsible for approximately 33% of
potential years of life lost (PYLL) due to all cancers in
males and approximately 20% of PYLL due to all can-
cers in females [1]. In males, it is also responsible for
approximately 30% of PYLL due to diseases of the heart
and 50% of PYLL due to respiratory diseases [1]. In
2002, over 2 million acute care hospital days (10.3% of
all acute care hospital days) in Canada were attributable
to smoking [2]. The cost of these smoking-attributable
acute care hospital days exceeded $2.5 billion. * Correspondence: john_cunningham@camh.net
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(20% of males and 16% of females) were identified as
current smokers in 2008. Although this proportion has
declined from 25% in 1999, it still represents 4.9 million
Canadian smokers [3]. Quitting smoking conveys
numerous immediate, intermediate and long term health
benefits. For example, coronary heart disease risk is
reduced by 50% after 12 months without smoking, and
after 15 years the risk is as low as that of a non-smoker.
Ten years after quitting the mortality rate from lung
cancer is about half that of a continuing smoker [4].
Helping smokers quit smoking should be a public health
priority.
In a systematic assessment of the value of clinical pre-
ventive services recommended by the U.S. Preventive
Services Task Force, smoking cessation treatment for
adults was one of the highest ranked services in terms
of its cost effectiveness and its potential to reduce the
burden of disease [5,6]. Smoking cessation services com-
pare favorably with other routine preventive health care
interventions such as screening for hypertension and
annual mammography. Most smoking cessation inter-
ventions cost less per year of life saved than most widely
accepted medical practices. For example, cost effective-
ness analysis of the implementation of the Agency for
Healthcare Research and Quality (AHRQ) [7] guidelines
show costs of $4,113 per life-year saved, in 2001 prices.
This compares favorably to annual mammography for
women aged 40 to 49 years, which costs $71,751 in
2001 prices, and hypertension screening for men aged
40+ years, which costs $27,117 in 2001 prices. A British
systematic analysis of smoking cessation interventions
found that Nicotine Replacement Therapy (NRT) costs
between £1000 and £2400 per year of life saved [8].
Large scale consumer consensus and population
research conducted across parts of the U.S. and Canada
has shown that mailed free NRT is an effective way of
promoting smoking cessation and of helping motivated
smokers who want to quit. Research conducted in New
York State found that 53% of smokers indicated that the
free distribution of NRT would be most effective in
motivating them to think seriously about stopping
smoking [9]. A Canadian population survey similarly
found that 58.9% of ≥ 10 cigarettes per day smokers
expressed interest in receiving free nicotine patches and
of those, almost all indicated they would use nicotine
patches to quit permanently [10]. Heavier smokers were
more likely than less heavy smokers to be interested in
receiving free NRT.
In an effort to increase access to smoking cessation
therapies, one program in New York State provided
over 40,000 smokers who called in to a Smokers’ Quit-
line with one to six weeks of free nicotine patches or
vouchers for two weeks of NRT. Evaluation of the
giveaway program revealed that Quit rates four months
later varied from 21% (among smokers receiving one
week of NRT for free) to 35% (among smokers receiving
6 weeks of NRT for free). This compared with a quit
rate of 12% among an earlier comparison group of call-
ers to the Quitline (not randomly assigned) who
received counseling support and some self-help materi-
als but no NRT [11]. In Ontario, Canada, the STOP
Study has distributed free NRT and thus far has been
responsible for the delivery of 5 weeks of free NRT to
approximately 58,000 smokers (representing roughly
33% of adult Ontario smokers who smoke ≥ 10 cigar-
ettes a day and who report wanting to quit in the next
30 days) [12]. As part of a call centre-based mass distri-
bution initiative, end-of-treatment quit rate (using 7 day
point prevalence) was estimated to be 15% (the calcula-
tion used as the denominator all those who were sent
NRT and assumed that all recipients who did not com-
plete their end-of-treatment survey had not quit). At the
6-month follow-up period, the quit rate based on 30 day
point prevalence was estimated to be approximately 9%
[12]. Of particular note, the majority (76%) of smokers
in the STOP Study requested nicotine patches as their
desired form of NRT.
Overall, the existing research suggests that smokers
are interested in easier access to smoking cessation
therapies, and that the receipt of such therapies, includ-
ing free NRT, seems to be associated with increased
rates of quitting smoking. However, none of the studies
exploring increased availability of NRT through mass
distribution were randomized controlled trials. As a
result, the findings are suggestive but do not permit
causal inference. Additionally, biochemical verification
of self-report abstinence was not performed in these
studies. Considerable money has been invested in mass
distribution of free NRT in Ontario and similar initia-
tives are being undertaken or contemplated in other
provinces. It is important at this stage to conduct a ran-
domized controlled study to determine the efficacy of
large scale distribution of free NRT.
Aim of the study
This study will attempt to answer the question, “does
mass distribution of the nicotine patch actually work (i.
e., increase quit rates significantly above those who do
not receive free nicotine patches)?” By conducting a ran-
domized controlled trial of free mass NRT distribution,
this study will evaluate the efficacy of the mass distribu-
tion approach. Comparison of an experimental group
which will be offered free nicotine patches to a control
group that does not get offered nicotine patches will
determine whether or not mass distribution of NRT is
an effective way of helping smokers quit. It is hypothe-
sized that among eligible Canadian smokers expressing
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domly selected to be offered 5 weeks of free nicotine
patches will exhibit a significantly greater quit rate at 8
weeks and 6-month follow-ups compared to those not
offered free nicotine patches (saliva cotinine measure-
ments used to validate self-reported smoking absti-
nence). Previously it has been shown that those who
metabolize nicotine more quickly have significantly
poorer cessation rates on nicotine patch than slow
metabolizers [13]. Therefore this study will also explore
whether fast nicotine metabolizers (as measured by the
3-Hydroxycotinine/cotinine ratio) will be less likely to
succeed at quitting smoking, as compared to slow nico-
tine metabolizers, when offered free nicotine patches.
Finally, the study will investigate how compliance with
recommended amount of NRT, and whether prior use
of NRT, affects success at quitting smoking when smo-
kers are offered free nicotine patches.
Methods/design
Design
This is a single-blind, randomized controlled trial of
mass distribution of free Nicotine Replacement Ther-
apy to Canadian smokers. A two-stage recruitment
process will be employed, in the context of a general
population survey with two follow-ups (8 weeks and 6
months). Random digit dialing of Canadian home tele-
phone numbers and an initial interview will identify
households with adult (age 18 or over) smokers who
smoke 10 or more cigarettes a day. One individual
from each household who is willing to take part in a
smoking study that involves three interviews, with sal-
iva collection for 3-HC/cotinine ratio measurement at
baseline and saliva cotinine verification at 8-week and
6-month follow-ups will be randomly selected (accord-
ing to most recent birthday). Willing participants will
be offered a $20 honorarium for completing the base-
line and each of the 8-week and 6-month follow-ups.
Verbal consent will be obtained as the initial contact is
by telephone.
As part of the baseline survey, eligible subjects will be
identified for the second stage of the recruitment pro-
cess and will be randomized into experimental and con-
trol conditions to receive versus not receive nicotine
patches. Eligibility will be determined by a series of
questions regarding hypothetical interest in nicotine
patches to quit smoking (including willingness to have
nicotine patches sent to their home) and having no con-
traindications for using NRT. A randomized half of the
eligible subjects will be assigned to the experimental
condition and asked for their permission to have nico-
tine patches sent to their home. These subjects will have
5 weeks of nicotine patches sent to their homes to help
them quit smoking. Subjects in the control condition
will not be offered nicotine patches. Only subjects in the
randomized controlled trial will be followed-up at 8
weeks and 6 months. See Figure 1 for a CONSORT dia-
gram of the proposed study design.
Ethical approval
The research methods to be used in this study have
been approved by the standing ethics review committee
of the Centre for Addiction and Mental Health.
Participants - inclusion and exclusion criteria
Participants will be recruited using a general population
telephone survey of Canadian residents. A two stage
recruitment procedure will be employed.
Criteria for Participation in baseline survey
Participation in the baseline recruitment survey will be
restricted to current smokers, age 18 and above, who
smoke 10 or more cigarettes per day, who are interested
in being involved in a smoking study, and who are will-
ing to answer three sets of questions: now, after 8 weeks
and after 6 months. In addition, participants must be
willing to provide a saliva sample for cotinine analysis at
each time point (sent by mail [14,15]; note that 97% of
cotinine samples collected by mail were usable in these
studies).
Criteria for Assignment to the Randomized Controlled Trial
As part of the baseline survey, all subjects will be asked
a series of questions to assess their level of interest in
receiving free NRT: “The Ministry of Health is consider-
ing different ways to help people stop smoking. One
option would be to provide interested smokers with free
Nicotine Patches. If Nicotine Patches were offered for
free, would you be interested in receiving them?” Those
who say “yes” will then be asked if they would use the
nicotine patch to quit smoking. Those who say “yes” to
this question will be asked if they would begin to use
the patch within 1 week of receiving it. A “yes” to this
question will lead to being asked if they would be will-
ing to have the Patch sent to their home. These ques-
tions have been used in a previous survey and form the
basis of the sample size estimate for the present study
[10]. Finally, as part of the demographic section of the
survey, subjects will also be asked questions regarding
health conditions contraindicating NRT use (i.e., being
pregnant, intending to become pregnant, or breastfeed-
ing; having a serious heart or circulation problem, not
including high blood pressure). Subjects will be eligible
for the randomized controlled trial if they are interested
in NRT, would use it to quit within 1 week of receipt,
are willing to have the NRT sent to their home, and
have no health contraindications for the use of NRT.
Subjects who meet all these eligibility criteria will then
be randomly assigned to the experimental or control
condition.
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used NRT in the past, they will not be excluded from
the study due to prior NRT use because the intent is to
evaluate the impact of NRT in the full range of potential
community participants. In addition, our previous
research has indicated that prior use of NRT is actually
positively related to current interest in using NRT again
[10]. Thus, one of the secondary analyses of this study
will test the moderating hypothesis that prior use of
NRT is negatively related to future success with NRT
when it is offered for free.
Interventions
Experimental condition
A randomized half of the subjects meeting baseline cri-
teria and expressing an interest in receiving free nicotine
3290 Canadian adults who smoke 10 or more 
cigarettes per day, recruited through general 
population telephone survey and willing to participate 
in baseline, 8-week and 6-month surveys with saliva 
collection 
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Figure 1 Overview of the proposed intervention trial.
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quit smoking, interest in having the patches sent to
their home, and meeting criteria for eligibility to receive
NRT (i.e., no health contraindications) will be randomly
assigned to the experimental condition (the remainder
will be assigned to the control condition). Subjects in
the experimental condition will be asked, at the end of
the baseline survey, if they want to be sent a free, 5-
week supply of Nicotine Patches. Those who say “yes”
will have the NRT mailed to their home the week after
their baseline interview. As is employed in the Ontario
mass distribution of NRT init i a t i v e[ 1 2 ] ,a5 - w e e kp r o -
gram of nicotine patches will be sent (3 weeks of Step 1
[21 mg of nicotine]; 1 week of Step 2 [14 mg of nico-
tine]; 1 week of Step 3 [7 mg of nicotine]). Once ran-
domly assigned to this condition, subjects will be
counted as part of the experimental condition whether
they agree to accept the NRT or not (intent-to-treat
approach).
The 5-week program of nicotine patches was chosen
for pragmatic reasons, which balanced a limited budget
to supply the NRT and conduct a large population sur-
vey, and because of findings from literature regarding
effective treatment duration. A recent Cochrane review
evaluating the efficacy of NRT has revealed no differ-
ences in treatment effect between trials offering up to
eight weeks of nicotine patch treatment and those offer-
ing longer treatments [16]. Furthermore, several trials
evaluating usage patterns of free nicotine patches offered
to smokers through a Smokers’ Quitline have shown no
differences in 7- and 12-month quit rates between indi-
viduals receiving 2, 4, 6, or 8-week supplies of free nico-
tine patches [17,18]. These findings however, are
inconsistent with two other studies demonstrating
higher quit rates among Smokers’ Quitline callers
receiving 8 weeks versus 2 weeks of free nicotine
patches [19], and 6 weeks versus 4 weeks of free NRT
[20]. Given the apparent inconsistencies in the literature
surrounding effective treatment duration of mailed out
free NRT, we chose a middle of the road approach of 5
week nicotine patch program.
Control condition
Subjects randomly assigned to the control condition will
n o tb ea s k e d ,a tt h ee n do ft h eb a s e l i n es u r v e y ,i ft h e y
want free nicotine patches sent to their homes. An
advantage of the design procedure to be employed in this
trial is that respondents in the control condition will not
have the expectation that they will receive NRT. Thus,
their smoking outcomes at 8-week and 6-month follow-
ups will reflect a true natural history comparison to the
outcomes of subjects in the experimental condition.
An alternate control condition would be to provide
subjects with placebo patches. However, the objective of
this trial is to test the question, “does mailed
distribution of free NRT (in the form of the nicotine
patch) lead to increased quit rates among Canadian
smokers?” This objective is a pragmatic one and
requires the random assignment of offering free NRT to
some and nothing to others. Whether the impact of the
NRT is due to the active ingredient or due to a placebo
effect is irrelevant to this objective. Thus, the most
appropriate control condition is one where subjects
receive nothing, and further, have no expectation that
they would receive anything.
Content of Baseline Interview
The primary purpose of the baseline interview is to
assess eligibility for the randomized controlled trial. Spe-
cifically, subjects will be asked of their interest in receiv-
ing free NRT, its use within one week of receipt, and
health contraindications for NRT use. In addition, other
questions will also investigate the following: a) subjects’
heaviness of smoking [21], b) number and duration of
past quit attempts, c) past use of NRT, d) current life
stressors, e) motivation to quit smoking, f) past and pre-
sent drug use, g) level of alcohol intake (AUDIT-C)
[22], h) presence of mental health disorders diagnosis,
and e) a series of demographic characteristics such as
age, gender, ethnicity, marital status, education and
employment status.
Content of 8-week and 6-month follow-up interviews
At 8-week and 6-month follow-ups, subjects who have
not quit will be asked how many cigarettes per day they
currently smoke and their intentions to quit smoking;
how soon after waking they smoke their first cigarette;
and if, since their baseline interview, they have stopped
smoking for even one day because they were trying to
quit. Subjects in the experimental condition will be
asked to evaluate their experiences with NRT and to
elaborate on their efforts to quit smoking. Specifically,
at 8-weeks subjects will be asked if they received the
NRT; how soon after receipt they began to use it; how
much of it (if any) they used; if relevant, why they did
not use any or all of it; whether or not they experienced
any withdrawal symptoms and which ones; and what
challenges they encountered to quitting/reducing. At 6-
months, subjects will be asked whether or not they pur-
chased additional NRT to help in their quit effort (what
type and how much); whether or not they plan to pur-
chase more NRT to quit or maintain their non-smoking;
if they have smoked in the past 30 days or reduced
from baseline, what benefits they have noticed; what
supports they had for quitting; and what additional
resources they sought to help them quit. These ques-
tions will be asked after the core smoking status out-
come measures have been assessed. Subjects in the
control condition will also be asked about their use of
NRT but the questions will be framed to reflect pur-
chase of NRT from sources other than this ongoing
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about their use of other smoking cessation aids.
Validation of self-report by saliva cotinine samples
Several studies have demonstrated the utility of collecting
saliva cotinine samples by mail using the same Salivette
sampling method proposed for this study [14,15]. While
clinically tobacco exposure is measured by quantifying
cotinine in either plasma or urine, salivary cotinine is a
reliable measure of nicotine or tobacco exposure that is
widely used in both clinical and epidemiological or popu-
lation-based studies [23-25]. Participants will be asked to
collect their saliva sample at baseline and on the day they
complete their follow-up interviews (saliva collection kits
mailed several days following baseline interview and one
week before each follow-up interview is due, along with a
reminder letter about the upcoming telephone interview).
At baseline, the saliva sample will allow for the calcula-
tion of the 3-HC/cotinine ratio to test the moderating
hypothesis of nicotine metabolism rate on success at
tobacco cessation using nicotine patches. Collection of
saliva samples at follow-up periods will allow for the veri-
fication of smoking abstinence.
Randomization
Recruitment is conducted using a Random Digit Dialing
survey with computer assisted telephone interview
(CATI) technology. At the end of the baseline interview,
eligible subjects will be allocated to experimental and
control conditions using a simple randomization without
replacement built into the CATI program (no stratifica-
tion or minimization given the large proposed sample
size in this trial).
Blinding
Interviewers will be blind to subjects’ condition because
they will be using the CATI technology. As the first
parts of the 8-week and 6-month follow-ups are identi-
cal for experimental and control conditions, they will
not know the intervention condition to which a subject
belongs until questions specific to the use of NRT are
asked near the end of the surveys (i.e., after the primary
outcome measures are assessed). Further, while it is pos-
sible that a participant might ‘unblind’ themselves to an
interviewer by volunteering that they used the nicotine
patch, this is still unlikely to have an impact as the
interviewers will be part of a separately contracted tele-
phone survey research firm and will not be aware of the
hypotheses of this research trial.
Outcome Measures
Primary outcome measures
The primary outcome measure will be 30 day point pre-
valence of abstinence at 6 months, validated by saliva
cotinine samples.
Secondary outcome measures
Secondary outcome measures are: (1) 7 day point preva-
lence of smoking abstinence at 8 weeks post-baseline;
(2) reduction in smoking since baseline; (3) compliance
with the full 5-week course of nicotine patches provided
to experimental condition; (4) challenges with quitting/
reducing smoking; and (5) purchase and use of NRT
and smoking cessation aids at follow-up periods.
Data Analysis
Power analysis
Quit rates for those who use nicotine patches have been
obtained from several sources, including systematic
reviews by Fiore et al. [26] and a Cochrane review by
Stead and colleagues [16]. Both these reviews indicate a
10% increase in tobacco cessation rates upon using nico-
tine patches as compared to placebo at 6-month follow-
up. This 10% increase is roughly in concordance with
the 30 day point prevalence rate for abstinence observed
at the 6-month follow-up point of the STOP mass dis-
tribution demonstration trial (9%; note that this trial
had no control group so the results reflect pre-post
changes in smoking rates) [12]. However, we recognize
that both of these estimates are probably too large for a
pragmatic randomized controlled trial because the
impact of interventions is often smaller in real world
settings (and pre-post estimates, such as those found in
the STOP Study, can also be inflated). Thus, we have
chosen to power our trial based on the assumption that
o u rq u i tr a t ew i l lb eh a l fa sl a r g e( i . e . ,a5 %i n c r e a s ei n
quit rates in the experimental condition versus the con-
trol at 6-month follow-up). Finally, we can estimate a
3.7% baseline rate of smoking cessation at 6-month fol-
low-up in a general population sample using findings
from the 2008 Canadian Tobacco Use Monitoring Sur-
vey (CTUMS) [3]. Given these results, we predict that
the subjects in the control condition will display a 3.7%
quit rate and subjects in the experimental condition will
display a 8.7% quit rate at 6-month follow-up.
Using these assumptions, a power analysis was con-
ducted; this indicated that a total of 403 respondents
would be needed per condition to detect a 5% difference
at a significance level of .05 with a power of 80% (esti-
mate calculated with continuity correction factored in)
[27]. Thus, we have chosen an ideal sample size of
approximately 800 respondents in order to conduct
appropriate analyses.
Based on our previous research using a similar
research design, albeit with problem drinkers rather
than smokers [28,29], a 20% attrition between baseline
and 6-month follow-up can be expected (the most
important follow-up for this study); this would mean
that a sample size of 1,000 respondents would be
needed at baseline to take part in the randomized trial.
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in the Ontario Tobacco Survey, indicating that a 20%
attrition rate estimate is also reasonable for smokers
[30].
From a recent survey of current smokers [10] we
know that 62% of 10 or more cigarettes a day smokers
say that they would be interested in receiving NRT.
Note that the 62% proportion is slightly different from
the 58.9% previously reported from this same survey.
This is because the proportion reported here for the
purposes of generating a sample size estimate was calcu-
lated using unweighted data and employs only those
smokers from this pilot survey who currently smoke 10
or more cigarettes per day (rather than all smokers who
smoked 10 or more cigarettes per day at some point in
their life as is employed in the published paper).
Further, from this same survey, we know that 57% of
t h o s ei n t e r e s t e di nf r e eN R Ts a yt h a tt h e yw o u l du s e
this NRT to quit, state they would start using it within a
week, and would also be willing to have it sent to their
homes. Finally, results from this same pilot survey indi-
cate that approximately 14% of those willing to have
NRT sent to their homes would screen out due to
health contraindications (heart or circulatory problems
not including high blood pressure; currently pregnant,
intending to become pregnant or breastfeeding) [10].
Note that this estimate of health contraindications is an
overly conservative one as the question on heart or cir-
culatory problems asked about lifetime experience.
Thus, it is likely that less than 14% of potential subjects
will be excluded for this reason. However, we will use
the 14% figure in this estimate in order to ensure an
adequate sample size.
In conclusion, in order to conduct this trial, we would
need to recruit approximately 3,000 respondents at
baseline who smoke 10 or more cigarettes per day and
who are also willing to take part in an 8-week and a 6-
month follow-up with saliva sample collection by mail
at each time point (note: saliva samples only collected
for the 1,000 participants at baseline who will take part
in the randomized trial).
Analysis Plan
The primary analyses will employ manual stepwise logis-
tic regressions. Specifically, dependent measures will be
30 day point prevalence abstinence at 6-month follow-
up and 7 day point prevalence abstinence at 8-week fol-
low-up. Separate logistic regression analyses will be con-
ducted for each time point (validated by saliva cotinine
sample). In the primary analyses, subjects lost to follow-
up will be assumed to be active smokers. In Step one of
the logistic regression, experimental condition will be
entered as a dummy coded variable (0 = control condi-
tion; 1 = experimental condition). This step will test the
primary hypothesis regarding the impact of sending free
NRT on quit rates. Steps two and three of the logistic
regression will involve adding interaction terms to test
the mediator and moderator hypotheses (3-HC/cotinine
ratio, compliance with NRT use, prior use of NRT;
main effects terms entered in Step two and interaction
terms entered in Step three). Sex difference analyses will
be conducted in a similar manner (i.e., is there an inter-
action effect of subjects’ sex by receipt of NRT on absti-
nence rates at 6-month follow-up?). As part of these
primary analyses, we will also conduct a chi-square test
to explore whether there is differential loss to follow-up
between experimental conditions. Further we will repli-
cate the primary analyses with all subjects with missing
data excluded from the analyses. If the results are the
same between the analyses where the missing data is
excluded and where subjects lost to follow-up are
assumed to still be current smokers, then we can safely
assume that there is no differential attrition between
conditions (or, at least none that impacted on the out-
come of the trial).
Subgroup analyses will examine quit rates among sub-
jects within the experimental and control conditions
who: (a) are slow versus fast nicotine metabolizers as
measured by the 3-HC/cotinine ratio; (b) report using
all 5 weeks of the free NRT they were sent as compared
with those who do not use all 5 weeks; (c) had used
NRT for a quit attempt at least once before participa-
tion in the proposed study as compared with those who
had never used NRT before; and (d) are male or female
(to assess any interaction by sex). Further, we will com-
pare subjects in the experimental condition who used
the NRT to just those subjects in the control condition
w h od i dn o tu s ea n yN R Td u r i n gt h es a m et i m ep e r i o d
(i.e., they did not obtain NRT from other sources).
Finally, using just the baseline data (N = 1,000), we will
relate the 3-HC/cotinine ratio to patterns of smoking
and prior use of NRT.
Discussion
There has been extensive research evaluating the effi-
cacy of NRT as a means to promote smoking cessation.
In a systematic review of 132 randomized controlled
trials involving NRT, Stead et al. [16] concluded that
NRTs increase the rate of quitting smoking by 50 to
70%, irrespective of the clinical setting in which the
smoker is treated. The Public Health Service in the U.S.
has, over the years, examined over 8,700 research arti-
cles in order to prepare guidelines for the treatment of
tobacco use and dependence [26]. They found that med-
ications such as NRTs are effective in increasing long-
term smoking abstinence rates and recommend that
clinicians encourage their use. They also found evidence
that health care policies, for example, insurance cover-
age of smoking cessation treatments, play an important
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smoking cessation treatment and thus successfully quit.
With the evidence supporting the efficacy of NRTs in
successful smoking cessation and with the recommenda-
tions from these reviews promoting increased access to
NRT for smokers, the undertaking of mass distribution
of free NRT appears to be well founded. However, there
have been no randomized controlled trials yet of mass
distribution of free NRTs to show whether or not such
an initiative would indeed result in a population level
quit rate above that attained without this intervention.
The present study would be the first such trial. In parti-
cular, employing a panel survey design, this randomized
controlled trial will evaluate the effectiveness of free
mass distribution of the nicotine patch to Canadian
smokers interested in free NRT. In contrast to subjects
in the experimental condition receiving a 5-week pro-
gram of nicotine patches, subjects in the control condi-
tion will not be offered free nicotine patches. At 8-week
and 6-month follow-ups, comparison of smoking out-
comes between the two groups will evaluate the effec-
tiveness of free NRT intervention and a naturalistic
progression of smokers interested in quitting but not
receiving such intervention.
The proposed trial will be useful to policy makers, in
particular Canadian policy makers, in the development
of public health initiatives to reduce the prevalence of
smoking. If the project finds support for the effective-
ness of supplying interested smokers with free NRT in
order to help them quit, it would provide evidence to
move forward with policies designed to make NRT
treatment readily and freely available to smokers who
request it.
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